Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
An Oncologist's View: Cancer Care & Self Care During Winter
An Oncologist's View: Cancer Care & Self Care During Winter
Confronting the Disparity Crisis in Breast Cancer Care
Confronting the Disparity Crisis in Breast Cancer Care
Exploring the Impacts of Race & Bias in Cancer Treatment
Exploring the Impacts of Race & Bias in Cancer Treatment
Assessing Advancements in Treatment Options for Small Cell Lung Cancer
Assessing Advancements in Treatment Options for Small Cell Lung Cancer
Exploring the Treatment Landscape for Head & Neck Cancer
Exploring the Treatment Landscape for Head & Neck Cancer
How COVID-19 Has Changed the Way We Approach Head & Neck Cancer Care
How COVID-19 Has Changed the Way We Approach Head & Neck Cancer Care
The COVID-19 Pandemic & Dangerous Delays in Cancer Screenings
The COVID-19 Pandemic & Dangerous Delays in Cancer Screenings
Higher Risk, Lowered Age: New Colorectal Cancer Screening Guidelines
Higher Risk, Lowered Age: New Colorectal Cancer Screening Guidelines
Not Quite a Cancer Vaccine: Selling HPV & Cervical Cancer
Not Quite a Cancer Vaccine: Selling HPV & Cervical Cancer
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
Pancreatic Cancer: The Hunt to Catch a Silent Killer
Pancreatic Cancer: The Hunt to Catch a Silent Killer
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
